Oncology

Clinical Study

Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia

Aldiab A.a · Al Khayal K.A.b · Al Obaid O.A.b · Alsheikh A.c · Alsaleh K.a · Shahid M.d · Alkharji H.a

Author affiliations

aDivision of Oncology, Department of Medicine, College of Medicine and University Hospital, King Saud University, bColorectal Research Centre, Department of Surgery, King Khalid University Hospital, College of Medicine, King Saud University, cDepartment of Pathology, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, and dDepartment of Genetics, College of Medicine, Prince Sattam bin Abdulaziz University, Alkharj, Kingdom of Saudi Arabia

Keywords: Colorectal cancerClinicopathological dataKRASBRAFOverall survival

Related Articles for ""
Oncology 2017;92:75-86
https://doi.org/10.1159/000450857

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: August 03, 2016
Accepted: September 01, 2016
Published online: December 03, 2016
Issue release date: January 2017

Number of Print Pages: 12
Number of Figures: 2
Number of Tables: 5

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Background/Aims: Colorectal cancer (CRC) is the most frequent cancer and a leading cause of cancer death in the Kingdom of Saudi Arabia (KSA). To date, no nationwide screening programs have been adopted. This prospective, longitudinal study investigated factors influencing the outcome of CRC in Saudi patients. Methods: Patients completed a CRC awareness questionnaire. Colonoscopy, CT/MRI, histopathology of tumor biopsies, and KRAS and BRAF testing were performed. Patients were treated according to their stage. All patients were followed until the end of the study and 3- and 5-year survival was assessed. Results: Sixty percent of study patients with sporadic CRC presented with significantly advanced disease (stages III and IV) with or without metastases at entry. Patients showed low levels of awareness of the risk factors and signs of CRC. Patients presented at a median age of 50 years. Family history of CRC and ulcerative colitis were positive in 11 and 6% of patients, respectively. Stage III/IV tumors with distant metastases at enrollment, right-sided tumors, mucinous tumors, lymphovascular invasion, and KRAS (51%) or BRAF (28%) mutations predicted poor prognosis and survival. Conclusion: CRC in KSA is usually diagnosed at advanced stages with metastases and KRAS/BRAF, and is associated with poor prognosis and short survival. Nationwide awareness campaigns and screening programs for CRC are critical for prevention, early detection and adequate management of CRC.

© 2016 S. Karger AG, Basel



Related Articles:

References

  1. World Health Organization, International Agency for Research on Cancer: Colorectal Cancer: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed April 27, 2016).
  2. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
  3. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
  4. Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S: Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Ann Saudi Med 2015;35:196-202.
  5. Al-Ahwal MS, Shafik YH, Al-Ahwal HM: First national survival data for colorectal cancer among Saudis between 1994 and 2004: what's next? BMC Public Health 2013;13:73.
  6. Ahmad M, Zubaidi, Noura M, et al: Public awareness of colorectal cancer in Saudi Arabia: a survey of 1,070 participants in Riyadh. Saudi J Gastroenterol 2015;21:78-83.
  7. Mosli MH, Al-Ahwal MS: Colorectal cancer in the Kingdom of Saudi Arabia: need for screening. Asian Pac J Cancer Prev 2012;13:3809-3813.
  8. Jass JR: Pathogenesis of colorectal cancer. Surg Clin North Am 2002;82:891-904.
  9. Heavey PM, McKenna D, Rowland IR: Colorectal cancer and the relationship between genes and the environment. Nutr Cancer 2004;48:124-141.
  10. Aune D, Chan DS, Lau R, et al: Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011;343:d6617.
  11. Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ: Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009;7:682-688.
  12. Jess T, Rungoe C, Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-649.
  13. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-2460.
  14. Pritchard CC, Grady WM: Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-129.
  15. Yamauchi M, Lochhead P, Morikawa T, et al: Colorectal cancer: a tale of two sides or a continuum? Gut 2012;61:794-797.
  16. Ogino S, Chan AT, Fuchs CS, et al: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411.
  17. Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T: A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 2015;15:258.
  18. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer with cetuximab. J Clin Oncol 2008;26:514.
  19. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-4632.
  20. Tejpar S, Bertagnolli M, Bosman F, et al: Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010;15:390-404.
  21. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
  22. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-4632.
  23. McCaffery K, Wardle J, Waller J: Knowledge, attitudes, and behavioral intentions in relation to the early detection of colorectal cancer in the United Kingdom. Prev Med 2003;36:525-535.
  24. Hamilton SR, Rubio CA, Vogelstein B, et al: Carcinoma of the colon and rectum; in Hamilton SR, Aaltonen LA (eds): World Health Organization classification of tumours of the digestive system. Lyon, IARC Press, 2000, pp 101-119.
  25. American Cancer Society: Colorectal cancer stages. http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-staged (accessed March 14, 2016).
  26. Hamilton SR, Bosman FT, Boffetta P, et al: Carcinoma of the colon and rectum; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC Press, 2010, pp 134-146.
  27. Edge SB, Byrd DR, Compton CC, et al: AJCC Cancer Staging Handbook, ed 7. New York, Springer, 2010, pp 173-206.
  28. Pinto P, et al: Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet 2011;204:439-446.
  29. Weichert W, et al: KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12:35-42.
  30. Wang HL, Lopategui J, Amin MB, et al: KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010;17:23-32.
  31. Benlloch S, Payá A, Alenda C, Bessa X, Mu A, Jover R, Castells A, Llor X, Aranda I, Massutí B: Detection of BRAF V600E mutation in colorectal cancer. J Mol Diagn 2006;8:540-543.
  32. American Cancer Society: Management of Colorectal cancer. http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-staged (accessed March 14, 2016).
  33. Wilmink ABM: Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483-493.
  34. Jasperson KW, Tuohy TM, Neklason DW, Burt R: Hereditary and familial colon cancer. Gastroenterology 2010;38:2044-2058.
  35. Shiovitz S, Copeland WK, Passarell MN, Burnett-Hartman AN, et al: Characterisation of familial colorectal cancer type X, Lynch syndrome, and non-familial colorectal cancer. Br J Cancer 2014;111:598-602.
  36. Mosli MH, Al-Ahwal MS: Colorectal cancer in the Kingdom of Saudi Arabia: need for screening. Asian Pac J Cancer Prev 2012;13:3809-3813.
  37. Butler LM, Millikan RC, Sinha R, et al: Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. Mutat Res 2008;638:162-174.
  38. Azeem S, Gillani SW, Siddiqui A, et al: Diet and colorectal cancer risk in Asia: a systematic review. Asian Pac J Cancer Prev 2015;16:5389-5396.
  39. Gingras D, Béliveau R: Colorectal cancer prevention through dietary and lifestyle modifications. Cancer Microenviron 2011;4:133-139.
  40. Memish ZA, El Bcheraoui C, Tuffaha M, Robinson M, Daoud F, Jaber S, et al: Obesity and Associated Factors - Kingdom of Saudi Arabia, 2013. Prev Chronic Dis 2014;11:140236.
  41. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, et al: Obesity in Saudi Arabia. Saudi Med J 2005;26:824-829.
  42. Alquarshi K, Aljabr K, Bouchari S: Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med 2011;31:19-23.
  43. Benedix F, Kube R, Meyer F, et al: Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53:57-64.
  44. Zauber A, Knudsen A, Rutter CM, Lansdorp-Vogelaar I, Kuntz KM: Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. Rockville, Agency for Healthcare Research and Quality, 2015, AHRQ publication 14-05203-EF-2.
  45. Loupakis F, Yang D, Yau L, Feng S, Cremolini C, et al: Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107. pii: dju427.
  46. Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, et al: Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 2012;19:2814-2821.
  47. Secco GB, Fardelli R, Campora E, Lapertosa G, Gentile R, Zoli S, et al: Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. Oncology 1994;51:30-34.
  48. Thota R, Fang X, Subbiah S: Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database. J Gastrointest Oncol 2014;5:18-24.
  49. Bader T, Ismail A: Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: propensity for lung metastasis. Alexandria J Med 2014;50:203-209.
  50. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, Fischer von Weikersthal L, Giessen-Jung C, Stahler A, Schmoll H, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A: Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants - pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 2016;27:1746-1753.
  51. Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA: Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther, Epub ahead of print.
  52. Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, Sanna G, Putzu C, Ortu S, Scartozzi M, Ionta MT, Baldino G, Sarobba G, Capelli F, Sedda T, Virdis L, Barca M, Gramignano G, Budroni M, Tanda F, Palmieri G: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. J Transl Med 2016;14:292.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: August 03, 2016
Accepted: September 01, 2016
Published online: December 03, 2016
Issue release date: January 2017

Number of Print Pages: 12
Number of Figures: 2
Number of Tables: 5

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2017, Vol.92, No. 2

January 2017

Free Supplementary Material

Article

Recommend This
TOP